vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Purple Innovation, Inc. (PRPL). Click either name above to swap in a different company.
Purple Innovation, Inc. is the larger business by last-quarter revenue ($140.7M vs $139.2M, roughly 1.0× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -2.3%, a 37.8% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 9.1%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-7.8M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 8.3%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Purple Carrot is a Needham, Massachusetts-based, and 100% plant-based meal kit company. Founded by Andy Levitt, it offers both prepared meals as well as meal kits to subscribers weekly. As stated in a 2022 article in Cosmopolitan, “each Purple Carrot meal kit results in 72% less carbon being released into the atmosphere as compared to the standard American meal.”
ADMA vs PRPL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $140.7M |
| Net Profit | $49.4M | $-3.2M |
| Gross Margin | 63.8% | 41.9% |
| Operating Margin | 45.1% | -1.6% |
| Net Margin | 35.5% | -2.3% |
| Revenue YoY | 18.4% | 9.1% |
| Net Profit YoY | -55.9% | 62.1% |
| EPS (diluted) | $0.20 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $140.7M | ||
| Q3 25 | $134.2M | $118.8M | ||
| Q2 25 | $122.0M | $105.1M | ||
| Q1 25 | $114.8M | $104.2M | ||
| Q4 24 | $117.5M | $129.0M | ||
| Q3 24 | $119.8M | $118.6M | ||
| Q2 24 | $107.2M | $120.3M | ||
| Q1 24 | $81.9M | $120.0M |
| Q4 25 | $49.4M | $-3.2M | ||
| Q3 25 | $36.4M | $-11.7M | ||
| Q2 25 | $34.2M | $-17.3M | ||
| Q1 25 | $26.9M | $-19.1M | ||
| Q4 24 | $111.9M | $-8.5M | ||
| Q3 24 | $35.9M | $-39.2M | ||
| Q2 24 | $32.1M | $27.0K | ||
| Q1 24 | $17.8M | $-50.2M |
| Q4 25 | 63.8% | 41.9% | ||
| Q3 25 | 56.3% | 42.8% | ||
| Q2 25 | 55.1% | 35.9% | ||
| Q1 25 | 53.2% | 39.4% | ||
| Q4 24 | 53.9% | 42.9% | ||
| Q3 24 | 49.8% | 29.7% | ||
| Q2 24 | 53.6% | 40.7% | ||
| Q1 24 | 47.8% | 34.8% |
| Q4 25 | 45.1% | -1.6% | ||
| Q3 25 | 38.0% | -10.2% | ||
| Q2 25 | 35.1% | -13.5% | ||
| Q1 25 | 30.4% | -13.9% | ||
| Q4 24 | 32.6% | -6.0% | ||
| Q3 24 | 33.1% | -39.5% | ||
| Q2 24 | 36.6% | -12.1% | ||
| Q1 24 | 26.7% | -19.3% |
| Q4 25 | 35.5% | -2.3% | ||
| Q3 25 | 27.1% | -9.9% | ||
| Q2 25 | 28.1% | -16.5% | ||
| Q1 25 | 23.4% | -18.4% | ||
| Q4 24 | 95.2% | -6.6% | ||
| Q3 24 | 30.0% | -33.1% | ||
| Q2 24 | 29.9% | 0.0% | ||
| Q1 24 | 21.7% | -41.8% |
| Q4 25 | $0.20 | $0.03 | ||
| Q3 25 | $0.15 | $0.11 | ||
| Q2 25 | $0.14 | $0.16 | ||
| Q1 25 | $0.11 | $0.18 | ||
| Q4 24 | $0.45 | $0.08 | ||
| Q3 24 | $0.15 | $0.36 | ||
| Q2 24 | $0.13 | $0.00 | ||
| Q1 24 | $0.08 | $0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $24.3M |
| Total DebtLower is stronger | $72.1M | $126.7M |
| Stockholders' EquityBook value | $477.3M | $-29.7M |
| Total Assets | $624.2M | $296.3M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $24.3M | ||
| Q3 25 | $61.4M | $32.4M | ||
| Q2 25 | $90.3M | $34.2M | ||
| Q1 25 | $71.6M | $21.6M | ||
| Q4 24 | $103.1M | $29.0M | ||
| Q3 24 | $86.7M | $23.4M | ||
| Q2 24 | $88.2M | $23.4M | ||
| Q1 24 | $45.3M | $34.5M |
| Q4 25 | $72.1M | $126.7M | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | $70.7M | ||
| Q3 24 | — | $50.8M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $-29.7M | ||
| Q3 25 | $431.2M | $-26.9M | ||
| Q2 25 | $398.3M | $-15.6M | ||
| Q1 25 | $373.4M | $1.3M | ||
| Q4 24 | $349.0M | $20.2M | ||
| Q3 24 | $231.9M | $28.0M | ||
| Q2 24 | $188.3M | $66.4M | ||
| Q1 24 | $153.7M | $65.5M |
| Q4 25 | $624.2M | $296.3M | ||
| Q3 25 | $568.7M | $302.1M | ||
| Q2 25 | $558.4M | $303.8M | ||
| Q1 25 | $510.6M | $293.8M | ||
| Q4 24 | $488.7M | $307.8M | ||
| Q3 24 | $390.6M | $309.3M | ||
| Q2 24 | $376.4M | $362.1M | ||
| Q1 24 | $350.9M | $382.1M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 3.50× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-5.8M |
| Free Cash FlowOCF − Capex | $34.6M | $-7.8M |
| FCF MarginFCF / Revenue | 24.8% | -5.5% |
| Capex IntensityCapex / Revenue | 0.8% | 1.4% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-41.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-5.8M | ||
| Q3 25 | $13.3M | $-968.0K | ||
| Q2 25 | $21.1M | $-4.0M | ||
| Q1 25 | $-19.7M | $-23.1M | ||
| Q4 24 | $50.2M | $6.8M | ||
| Q3 24 | $25.0M | $1.1M | ||
| Q2 24 | $45.6M | $-8.9M | ||
| Q1 24 | $-2.2M | $-16.8M |
| Q4 25 | $34.6M | $-7.8M | ||
| Q3 25 | $-1.1M | $-1.8M | ||
| Q2 25 | $18.7M | $-7.0M | ||
| Q1 25 | $-24.4M | $-25.3M | ||
| Q4 24 | $47.5M | $5.7M | ||
| Q3 24 | $24.0M | $101.0K | ||
| Q2 24 | $43.6M | $-11.0M | ||
| Q1 24 | $-4.6M | $-19.9M |
| Q4 25 | 24.8% | -5.5% | ||
| Q3 25 | -0.8% | -1.5% | ||
| Q2 25 | 15.3% | -6.6% | ||
| Q1 25 | -21.2% | -24.3% | ||
| Q4 24 | 40.4% | 4.4% | ||
| Q3 24 | 20.0% | 0.1% | ||
| Q2 24 | 40.7% | -9.2% | ||
| Q1 24 | -5.6% | -16.5% |
| Q4 25 | 0.8% | 1.4% | ||
| Q3 25 | 10.7% | 0.7% | ||
| Q2 25 | 2.0% | 2.8% | ||
| Q1 25 | 4.1% | 2.2% | ||
| Q4 24 | 2.3% | 0.8% | ||
| Q3 24 | 0.9% | 0.9% | ||
| Q2 24 | 1.9% | 1.7% | ||
| Q1 24 | 2.9% | 2.5% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | -330.22× | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
